Vimarsana.com

Latest Breaking News On - Fran gregory - Page 1 : vimarsana.com

Asembia 2024: Addressing Access and Affordability Issues With Collaboration

In 2024, the Asembia Specialty Pharmacy Summit celebrated 20 years and speakers highlighted the conversations around improving access and affordability taking place at the meeting.

Nevada
United-states
Fran-gregory
Joe-depinto
Christie-smith
Jon-mahrt
Las-vegas
Frier-levitt
Health-outcomes
Mckesson
Cardinal-health
Asembia-specialty-pharmacy-summit

Biosimilars Could Fuel Potential Cost Savings in Health Care

Fran Gregory discusses the challenges posed by rising drug costs and emphasized that optimizing the use of biosimilars, which are entering the market at much lower prices than their reference products.

Fran-gregory

Preferred Positioning of Biosimilars a Powerful Lever for Adoption, Says Dr Fran Gregory

There are multiple levers that need to be pulled to allow biosimilars to come to market more broadly in the US, explained Fran Gregory, PharmD, MBA, vice president of emerging therapies, Cardinal Health.

Nevada
United-states
Jerrica-mathis
Travis-tate
Las-vegas
Fran-gregory
Cardinal-health
Specialty-pharmacy-summit
Biosimilars
Cpbm
Payer

2025 Cell & Gene Therapy Reimbursement Outlook

2025 Cell & Gene Therapy Reimbursement Outlook
genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.

United-states
Americans
Fran-gregory
Technology-payment
Cardinal-health
Centers-for-medicare-medicaid-services
Office-of-tissues
Gene-therapy-access-model
Medicaid-services
New-technology-add-on-payment
Vertex-pharmaceutical
President-biden

Biosimilars in Retina Space Expected to Grow in 2024, Coming Years

In a review, investigators focused on ranibizumab (Lucentis; Genentech), aflibercept (Eylea; Regeneron), and bevacizumab (Avastin; Genentech) as growth opportunities in the biosimilar space.

China
United-states
P-biocon-biologics
Samsung-bioepis
Fran-gregory
Coherus-biosciences
Genentech
Therapies-at-cardinal-health
Momenta-pharmaceuticals
Amgen
Pivotal-year
Pharmacy-times

Gene therapies are expensive, but generic versions are emerging

Biosimilars cost on average 50% less than biologic drugs, which could save patients with things like cancer and MS, a lot of money

Fran-gregory
Cardinal-healthhas
Cardinal-health

Gene therapies are expensive, but generic versions are emerging

Biosimilars cost on average 50% less than biologic drugs, which could save patients with things like cancer and MS, a lot of money

Cardinal-healthhas
Fran-gregory
Cardinal-health

Gene therapies are expensive, but generic versions are emerging

Biosimilars cost on average 50% less than biologic drugs, which could save patients with things like cancer and MS, a lot of money

Cardinal-healthhas
Fran-gregory
Cardinal-health

Cardinal Health annual research report examines milestone year in biosimilars

Study reveals impact of dramatic increase in commercially available biosimilars and progress in the areas of patient accessibility and treatment affordability DUBLIN, Ohio, Feb. 29, 2024...

Dublin
Ireland
Ohio
United-states
Tori-simmons
Fran-gregory
Cardinal-health-emerging-therapies
Cardinal-health
Cardinal-health-emerging
Markets

vimarsana © 2020. All Rights Reserved.